Vaccine Industry Procurement Intelligence And Opportunities 2020-2027Posted by Manisha S on February 7th, 2022 A vaccine is a suspension of weakened, killed, or fragmented microorganisms or toxins or of antibodies or lymphocytes that is administered to stimulate the body\'s immune response against the specific infectious agent or disease. Intramuscular is the most common mode of administration for vaccines. Majorly vaccines can be categorized into the following types based on their characteristics:
Read report summary or request a free sample copy of the report “Vaccine Industry Procurement Intelligence, Supplier Intelligence, Supplier Ranking, Pricing & Cost Structure Intelligence, Best Practices, Engagement Model, Low & Best Cost Country, Day One Analysis Report, 2020 – 2027” Demand Outlook The global vaccine market was valued at USD 42 billion in 2020 and it is expected to grow at a CAGR of 7-8% from 2020 to 2027 due to the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government investments for vaccine development, and the rising focus on immunization. According to WHO immunization awareness and government initiatives have helped prevent 2-3 million deaths annually before Covid-19. The recombinant/conjugate vaccine segment is the largest market share of ~55% followed by inactivated and live attenuated vaccines. North America generated more than 35% of revenue of the global vaccine market owing to strong awareness, secure government policies regarding health welfare. Cost Drivers Vaccine manufacturing costs can be divided into two segments. Fixed costs and variable costs. Fixed costs include product development, facilities, and equipment costs. Variable costs include consumables, direct labor, licensing/regularization, commercialization, and overhead costs. Vaccine production costs have a significant fixed cost component, reaching up to 90% of total costs. Production costs per unit can be reduced significantly through gains in productivity and economies of scale. Because of the high fixed cost element, the cost of production per dose decreases with increasing batch size. For bulk production, equipment cost is the major cost component with more than 40% share in the overall cost of production. Whereas for lab-scale production the product development and raw material costs plays important role in determining the overall cost of production. Browse our other Reports:
Key Players:
The global vaccine industry features a moderately consolidated landscape with the leading players contributing around 55% of the market share. Industry leaders are strengthening their presence through multiple mergers and acquisitions. About us: A smart and effective supply chain is essential for growth in any organization. Pipeline division at Grand View Research provides detailed insights on every aspect of the supply chain which helps in efficient procurement decisions. Our services include (not limited to): Market Intelligence involving - market size and forecast, growth factors, and driving trends Price and Cost Intelligence - pricing models adopted for the category, the total cost of ownership Supplier Intelligence - rich insight on supplier landscape, and identifies suppliers who are dominating, emerging, lounging, and specializing Sourcing / Procurement Intelligence - best practices followed in the industry, identifying standard KPIs and SLAs, peer analysis, negotiation strategies to be utilized with the suppliers, and best-suited countries for sourcing to minimize supply chain disruption Our market/procurement Intelligence reports include in-depth and actionable insights that help clients in understanding the different aspects of the supply chain and take more effective decisions. Like it? Share it! More by this author |